Cardiogenic Shock Teams Again Tied to Lower Mortality Cardiogenic Shock Teams Again Tied to Lower Mortality
New data suggest centers with a shock team had higher survival and lower resource use in the cardiac ICU.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 21, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Milrinone, Dobutamine Similarly Effective for Cardiogenic Shock
FRIDAY, Aug. 20, 2021 -- Results from a pragmatic randomized, double-blind clinical trial indicate that milrinone and dobutamine yield similar outcomes in the treatment of cardiogenic shock, according to a study published in the Aug. 5 issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 20, 2021 Category: Pharmaceuticals Source Type: news
Aug 13 2021 This Week in Cardiology Aug 13 2021 This Week in Cardiology
COVID-19, vaccine-induced myocarditis, Watchman complications, SGLT2 inhibitors, and cardiogenic shock are the topics John Mandrola, MD, discusses in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 14, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news
No Win for Milrinone Over Dobutamine in Cardiogenic Shock No Win for Milrinone Over Dobutamine in Cardiogenic Shock
Contrary to expectations, the long-awaited double-blind DOREMI trial was"another swing and a miss" for the field.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 6, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Higher MI Shock Survival With NCSI Protocol: Final Results Higher MI Shock Survival With NCSI Protocol: Final Results
Final results of the National Cardiogenic Shock Initiative show better survival rates in acute MI cardiogenic shock than seen in previous North American studies, but 1-year mortality remains a problem.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 29, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis, Expert opinion on investigational drugs 30(2): 95-102
Sepsis is a major health problem with a high incidence and mortality. ADM, a free-circulating peptide mainly expressed and secreted by vascular endothelial cells, shows vasodilatory properties and causes hypotension when present in higher concentrations during sepsis. Areas covered : Adrecizumab (ADZ) (HAM 8101) is a humanized targeted therapy directed against the N-terminus of adrenomedullin (ADM). ADZ inhibits excessive circulating sepsis-induced ADM and stimulates protective effects on the endothelial barrier, and decreases interstitial vasodilatory effects. ADZ demonstrated a promising safety profile in healthy subject...
Source: Current Awareness Service for Health (CASH) - March 4, 2021 Category: Consumer Health News Source Type: news
ESC Acute CardioVascular Care 2021: Delivering urgent cardiac care during a pandemic
(European Society of Cardiology) International experience on treatment of COVID-19 and maintaining emergency cardiac services during the pandemic will be revealed at ESC Acute CardioVascular Care 2021, an online scientific congress of the European Society of Cardiology (ESC). Acute cardiovascular care is the specialty of cardiology dealing with critically ill cardiac patients suffering from urgent and life-threatening conditions including heart attack, cardiac arrest, acute heart failure, cardiogenic shock and others. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 15, 2021 Category: International Medicine & Public Health Source Type: news
Budget impact of using Impella 5.0 device for cardiogenic shock: savings projected in France
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news
Cardiogenic Shock Rate Soars in COVID-Positive ACS Cardiogenic Shock Rate Soars in COVID-Positive ACS
New registry data show COVID patients undergoing invasive reatment for acute coronary syndrome presented later, had more shock and much higher mortality than historical controls.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 22, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
MitraClip Effective for Post-MI Acute MR With Cardiogenic Shock MitraClip Effective for Post-MI Acute MR With Cardiogenic Shock
Percutaneous mitral valve repair with the MitraClip appears to be a safe, effective, and life-saving treatment for severe acute MR secondary to MI in surgical noncandidates, according to IREMMI data.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 19, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Women With AMI - Cardiogenic Shock Treated Less Aggressively
Coronary angiography, PCI, mechanical circulatory support used less often; mortality higher (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 29, 2020 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Gynecology, Internal Medicine, Critical Care, Emergency Medicine, Pulmonology, Journal, Source Type: news
Women With AMI-Cardiogenic Shock Treated Less Aggressively
TUESDAY, Sept. 29, 2020 -- Among young adults with acute myocardial infarction-cardiogenic shock (AMI-CS), women are treated less aggressively and have higher in-hospital mortality than men, according to a study published online Sept. 29 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 29, 2020 Category: Pharmaceuticals Source Type: news
HIV Patients Don't Have Worse Outcome After MI With Cardiogenic Shock HIV Patients Don't Have Worse Outcome After MI With Cardiogenic Shock
Outcomes of myocardial infarction-cardiogenic shock (AMI-CS) in patients with HIV but without AIDS are no worse than in patients without HIV, according to new findings.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 31, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Heart attack warning: How often do you pee? It could be a symptom of cardiogenic shock
A HEART ATTACK - otherwise known as a myocardial infarction - occurs when the blood supply to the heart has been blocked. Symptoms of the condition include chest pain, shortness of breath and feeling lightheaded. However, that may not be the worst of it. (Source: Daily Express - Health)
Source: Daily Express - Health - August 16, 2020 Category: Consumer Health News Source Type: news
DoD Funds Clinical Trial of Seraph Blood Filter to Treat COVID-19
The Department of Defense is funding a clinical trial of a COVID-19 treatment using ExThera Medical’s Seraph 100 Blood filter.
The device was selected to be in the multi-center randomized clinical trial because it showed encouraging preliminary results in critically ill COVID-19 patients at a military hospital in the U.S. and 14 other hospitals in Europe. Investigators at the Uniformed Services University in Bethesda will run the trial of the Martinez, CA-based company’s device. Initial reports indicate Seraph 100 stabilizes blood pressure and inflammatory biomarkers that correlate with ...
Source: MDDI - June 10, 2020 Category: Medical Devices Authors: Omar Ford Tags: COVID-19 Business Source Type: news
